A reduction was seen in the risk for readmission, wound dehiscence and hematoma, but no significant differences were seen in rates of infection and bleeding.
The US Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) respiratory syncytial ...